Pertuzumab + Trastuzumab - pc.00339.2026

This tender concerns the procurement of Pertuzumab and Trastuzumab, identified by the reference number pc.00339.2026. Pertuzumab and Trastuzumab are targeted therapies used primarily in the treatment of certain types of cancer, particularly HER2-positive breast cancer. Pertuzumab is a monoclonal antibody that inhibits the HER2 receptor dimerization, while Trastuzumab is also a monoclonal antibody that targets the HER2 protein. Their combined use has shown significant efficacy in improving outcomes for patients with HER2-positive breast cancer. The tender likely seeks to secure a supply of these critical medications, possibly for a public health program, hospital, or research institution. The specific quantity, dosage forms, and delivery timelines would be detailed in the full tender documentation. This procurement is essential for providing advanced cancer treatment options to patients who can benefit from these specific targeted therapies, underscoring the importance of reliable access to such pharmaceuticals within healthcare systems.

This is a supplies contract in the health and medical services, Research and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 124,782.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.